MX339765B - Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal. - Google Patents

Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.

Info

Publication number
MX339765B
MX339765B MX2012008955A MX2012008955A MX339765B MX 339765 B MX339765 B MX 339765B MX 2012008955 A MX2012008955 A MX 2012008955A MX 2012008955 A MX2012008955 A MX 2012008955A MX 339765 B MX339765 B MX 339765B
Authority
MX
Mexico
Prior art keywords
renal
prognosis
diagnosis
compositions
methods
Prior art date
Application number
MX2012008955A
Other languages
English (en)
Other versions
MX2012008955A (es
Inventor
Joseph Anderberg
Jeff Gray
Paul Mcpherson
Kevin Nakamura
James Patrick Kampf
Original Assignee
Astute Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astute Medical Inc filed Critical Astute Medical Inc
Publication of MX2012008955A publication Critical patent/MX2012008955A/es
Publication of MX339765B publication Critical patent/MX339765B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/524—Thrombopoietin, i.e. C-MPL ligand
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5409—IL-5
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/585—Calcitonins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos y composiciones para supervisar, diagnosticar, pronosticar, y determinar regímenes de tratamiento en sujetos que sufren de o se sospecha tienen una lesión renal. Particularmente, la invención se refiere a usar uno o más ensayos configurados para detectar un marcador de lesión del riñón seleccionado del grupo que consiste delnterleucina-5, subunidad beta del receptor de Interleucina-6, factor de tejido, globulina que liga a hormona del sexo, Alfa-2-macroglobulina, Apolipoproteína A-I, Calcitonina, Trombopoyetina, proteína C-reactiva, molécula de adhesión intercelular 3, metalloelastasa de macrófago, Apolipoproteína B-100, y fibrinógeno como biomarcadores de diagnóstico y pronóstico en lesiones renales.
MX2012008955A 2010-02-05 2011-02-04 Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal. MX339765B (es)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US30204810P 2010-02-05 2010-02-05
US30198510P 2010-02-05 2010-02-05
US30203210P 2010-02-05 2010-02-05
US30204710P 2010-02-05 2010-02-05
US30201610P 2010-02-05 2010-02-05
US30196110P 2010-02-05 2010-02-05
US30203910P 2010-02-05 2010-02-05
US30204510P 2010-02-05 2010-02-05
US30198110P 2010-02-05 2010-02-05
US30201210P 2010-02-05 2010-02-05
US30197010P 2010-02-05 2010-02-05
US30200910P 2010-02-05 2010-02-05
US30199210P 2010-02-05 2010-02-05
PCT/US2011/023832 WO2011097541A2 (en) 2010-02-05 2011-02-04 Methods and compositions for diagnosis and prognosis of renal injury and renal failure

Publications (2)

Publication Number Publication Date
MX2012008955A MX2012008955A (es) 2012-11-23
MX339765B true MX339765B (es) 2016-06-08

Family

ID=44356097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012008955A MX339765B (es) 2010-02-05 2011-02-04 Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.

Country Status (11)

Country Link
US (1) US20130230871A1 (es)
EP (1) EP2531622B1 (es)
JP (2) JP5998055B2 (es)
CN (1) CN102884205B (es)
AU (1) AU2011213686B2 (es)
CA (1) CA2788829A1 (es)
EA (1) EA201290627A1 (es)
HK (1) HK1174367A1 (es)
MX (1) MX339765B (es)
NZ (1) NZ601648A (es)
WO (1) WO2011097541A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012078736A2 (en) * 2010-12-09 2012-06-14 The Brigham And Women's Hospital, Inc. Fibrinogen and kidney damage
CA2944990A1 (en) 2014-04-09 2015-10-15 The Regents Of The University Of California Protein biomarkers for immune assessment and prediction of transplant rejection
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
US11244760B2 (en) 2015-06-25 2022-02-08 Karydo Therapeutix, Inc. Prediction device based on inter-organ cross talk system
GB201511207D0 (en) * 2015-06-25 2015-08-12 Xvivo Perfusion Ab Isolated organ evaluation and treatment
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
WO2017170610A1 (ja) * 2016-03-29 2017-10-05 株式会社国際電気通信基礎技術研究所 腎機能低下、慢性腎疾患及び腎不全からなる群から選択される少なくとも一種の疾患を予防、又は治療するための有効成分の候補物質のスクリーニング方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
JPH02275359A (ja) * 1989-04-18 1990-11-09 Teijin Ltd 腎疾患の診断方法、診断試薬およびキット
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
CA2072758A1 (en) 1990-09-14 1992-03-15 Kenneth Francis Buechler Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5955377A (en) 1991-02-11 1999-09-21 Biostar, Inc. Methods and kits for the amplification of thin film based assays
EP0585310B1 (en) 1991-04-10 1999-03-17 Biosite Diagnostics Inc. Crosstalk inhibitors and their uses
AU1911592A (en) 1991-04-10 1992-11-17 Biosite Diagnostics Incorporated Novel conjugates and assays for simultaneous detection of multiple ligands
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US5947124A (en) 1997-03-11 1999-09-07 Biosite Diagnostics Incorporated Diagnostic for determining the time of a heart attack
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
FR2872579B1 (fr) * 2004-06-30 2006-11-24 Pasteur Institut Detection de la tuberculose et de l'infection par mycobacterium tuberculosis a l'aide de hbha
CA2596469A1 (en) * 2005-02-01 2006-08-10 Government Of The U.S.A, As Represented By The Secretary Department Of H Ealth & Human Services Biomarkers for tissue status
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
WO2007106781A2 (en) * 2006-03-10 2007-09-20 University Of Rochester Ecg-based differentiation of lqt1 and lqt2 mutation
WO2008084331A2 (en) * 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
EP2469282A1 (en) * 2006-09-08 2012-06-27 University of Oxford Clinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
EP2257813A4 (en) * 2008-03-12 2011-11-02 Univ Columbia NGAL WITH HIGH MOLECULAR WEIGHT AS BIOMARKER FOR CHRONIC KIDNEY DISEASE

Also Published As

Publication number Publication date
EP2531622A4 (en) 2013-07-17
EA201290627A1 (ru) 2013-05-30
JP6186400B2 (ja) 2017-08-23
EP2531622A2 (en) 2012-12-12
CN102884205B (zh) 2016-05-04
EP2531622B1 (en) 2016-04-06
MX2012008955A (es) 2012-11-23
JP2013519866A (ja) 2013-05-30
CN102884205A (zh) 2013-01-16
AU2011213686A1 (en) 2012-08-30
NZ601648A (en) 2015-05-29
AU2011213686B2 (en) 2015-11-12
US20130230871A1 (en) 2013-09-05
JP2016006430A (ja) 2016-01-14
CA2788829A1 (en) 2011-08-11
HK1174367A1 (zh) 2013-06-07
WO2011097541A2 (en) 2011-08-11
WO2011097541A3 (en) 2011-11-10
JP5998055B2 (ja) 2016-09-28

Similar Documents

Publication Publication Date Title
MX339765B (es) Metodos y composiciones para diagnostico y pronostico de lesion renal y falla renal.
EP3070474A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EA201290629A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EP2585827A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
MX2011004767A (es) Metodos y composiciones para diagnosis y prognosis de lesion renal y falla renal.
EP2767833A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2813848A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
MX2012001559A (es) Metodos y composiciones para diagnosticos y pronosticos de lesion renal y falla renal.
NZ630277A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2811036A3 (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2008061149A3 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
MX2013000916A (es) Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales.
MX2014000283A (es) Metodos y composiciones para diagnóstico y pronóstico de lesión e insuficiencia renal.
WO2013039477A8 (en) Non-invasive methods of detecting target molecules
EA201290387A1 (ru) Способы и композиции для диагностики и прогнозирования повреждений почек и почечной недостаточности
EP2585826A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSING AND PROGNOSING RENAL INJURY AND RENAL FAILURE
WO2009083950A3 (en) Biomarkers for the prediction of renal injury
NZ608316A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2012175672A3 (en) Diagnosis and/or prognosis of parkinson's disease dementia
BR112015014232A2 (pt) lesão renal aguda
NZ605640A (en) Signal biomarkers
IN2014MN01759A (es)
WO2012167887A8 (en) Diagnostic use of prosomatostatin
WO2012040264A3 (en) Diagnostic tests for immune reactivity with human endothelial cell growth factor
FR2936060B1 (fr) Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire.

Legal Events

Date Code Title Description
FG Grant or registration